“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

Amneal Pharmaceuticals (AMRX) “announced that the FDA has accepted for review its Biologics Licensing Application for two proposed denosumab ...

followed by the approval of Zirabev (bevacizumab-bvzr; Pfizer) in June 2019. 2 In 2022, both Alymsys (bevacizumab-maly; Amneal Pharmaceuticals) and Vegzelma (bevacizumab-adcd; Celltrion Healthcare) ...

Whether you can have niraparib or rucaparib may depend on whether you don’t have a change in the BRCA1 or BRCA2 genes. Bevacizumab is a type of targeted drug called an anti angiogenic drug. These ...

and Alymsys (bevacizumab-maly), created under a partnership with mAbxience. By working with partners, Amneal controls costs and guarantees supplies. Late last year, the FDA approved Celltrion’s ...